NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) shares fell 1.6% during trading on Monday . The company traded as low as $0.56 and last traded at $0.60, 2,566 shares changed hands during trading. A decline of 100% from the average session volume of 1,129,628 shares. The stock had previously closed at $0.61.
Separately, LADENBURG THALM/SH SH started coverage on shares of NovaBay Pharmaceuticals in a research note on Wednesday, September 18th. They set a “buy” rating and a $1.10 price target for the company.
The company’s fifty day moving average price is $0.68 and its two-hundred day moving average price is $1.02.
About NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.
Featured Story: The role of implied volatility with call option volume
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.